Medical News

RSS

ARCA biopharma announces SPA agreement with FDA for bucindolol clinical trial

ARCA biopharma, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a clinical trial to assess the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to bucindolol. Bucindolol is the Company's investigational, pharmacologically unique, beta-blocker and mild vasodilator.

17 May 2010

Inovio Biomedical changes corporate name to Inovio Pharmaceuticals

Inovio Biomedical Corporation, a leader in the development of new preventive and therapeutic vaccines against cancers and infectious diseases, announced today that it has changed its corporate name to Inovio Pharmaceuticals, Inc. by filing a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware on May 14, 2010. Inovio's trading symbol remains the same.

17 May 2010

Soligenix first-quarter revenues decrease to $336,000

Soligenix, Inc., a late-stage biopharmaceutical company, announced today its financial results for the first quarter of 2010.

17 May 2010

Halozyme announces voluntary HYLENEX product recall

Halozyme Therapeutics, Inc. today announced that Halozyme and Baxter have confirmed the presence of small flake-like glass particles in a limited number of vials of HYLENEX® (hyaluronidase human injection) product at the Baxter manufacturing facility. Earlier today, Halozyme notified the U.S. Food and Drug Administration that it is voluntarily recalling affected lots of 150U HYLENEX product from distribution.

17 May 2010

Providence Equity Partners to acquire Virtual Radiologic for $17.25 per share

Virtual Radiologic Corporation, a national radiology practice and a leader in the development of radiologist workflow technology, and Providence Equity Partners, a leading global private equity firm that manages over $22 billion in equity capital, today announced that they have entered into a definitive agreement under which Providence will acquire all of the outstanding common stock of vRad for $17.25 per share in cash.

17 May 2010

Emergent BioSolutions' anthrax monoclonal antibody IND for Phase I study clears FDA review

Emergent BioSolutions Inc. announced today that its Investigational New Drug (IND) application, to commence a Phase I clinical trial for its anthrax monoclonal antibody therapeutic, has cleared U.S. Food and Drug Administration (FDA) review. The Phase I study will evaluate the safety and pharmacokinetics of the company's fully human monoclonal antibody being developed as a parenteral post-exposure therapy for individuals who have symptoms of anthrax disease. In pre-clinical therapeutic studies, Emergent's monoclonal antibody was found to be effective.

17 May 2010

Neovasc first-quarter revenues increase nearly 300% to $1.06 million

Neovasc Inc., today announced financial results for the three months ended March 31, 2009.

17 May 2010

NanoViricides signs Research Agreement with UCSF for testing anti-HIV drug candidates

NanoViricides, Inc., announced that it has signed a Research Agreement with the University of California, San Francisco for testing of its anti-HIV drug candidates. Cheryl Stoddart, PhD, Assistant Professor in the UCSF Division of Experimental Medicine, will be the Principal Investigator.

17 May 2010

Aeterna Zentaris' AEZS-108 receives orphan medicinal product designation for ovarian cancer in Europe

Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for its compound AEZS-108 for the treatment of ovarian cancer. AEZS-108, the Company's doxorubicin targeted conjugate compound, is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

17 May 2010

LLS's School & Youth Programs raise $1M to help fight against childhood cancer

Participants in The Leukemia & Lymphoma Society's Greater Los Angeles Chapter School & Youth(SM) Programs raised an unprecedented $1 million this spring, in a campaign that gives kids a chance to help in the fight against blood cancers.

17 May 2010

Tiens Biotech first-quarter revenues decrease to $11.4 million

Tiens Biotech Group (USA), Inc.,, today announced financial results for the first quarter ended March 31, 2010.

17 May 2010

Freescale Semiconductor receives ZigBee Certification for wireless health and wellness solutions

Freescale Semiconductor today announced it has received ZigBee Certified product status for its ZigBee Health Care wireless health and wellness processing platforms. The ZigBee Certified products status is awarded to products that have been tested and met criteria for interoperability that enable wireless devices to securely and reliably monitor and manage noncritical, low-acuity health care services.

17 May 2010

Celldex Therapeutics commences screening in CDX-1307 Phase 2 study for bladder cancer

Celldex Therapeutics, Inc. today announced that the first patient has been screened in a randomized Phase 2 study of the Company's novel, first-in-class antibody-based vaccine candidate from its Precision Targeted Immunotherapy (PTI) platform. This study will evaluate the CDX-1307 regimen in both neoadjuvant and adjuvant settings in patients with newly diagnosed muscle-invasive bladder cancers that express hCG-beta.

17 May 2010

Biostar Pharmaceuticals first-quarter 2010 revenues increase 66.0% to $12.4 million

Biostar Pharmaceuticals, Inc., a Xianyang- based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules, and a variety of pharmaceutical products, today announced financial results of the first quarter ended March 31, 2010.

17 May 2010

AngioDynamics launches Morpheus Smart PICC Triple Lumen CT PICC

AngioDynamics announced today the launch of the first member of its new generation of peripherally inserted central catheters (PICCs) for procedures involving the use of contrast media in computed tomography (CT) - the Morpheus Smart PICC Triple Lumen CT PICC.

17 May 2010

First Edition: May 17, 2010

Today's headlines highlight stories about efforts to advance the implementation of federal health reforms as well as the sweeping measure's political impact in primary races across the country.

17 May 2010

Jiangbo Pharmaceuticals third-quarter revenue decreases 0.6% to $25.6 million

Jiangbo Pharmaceuticals, Inc., a pharmaceutical company with its principal operations in the People's Republic of China, today announced financial results for the third quarter fiscal year 2010 ended March 31, 2010.

17 May 2010

MicroStockProfit.com: BSMD's total worldwide revenues for first-quarter 2010 decline 2%

MicroStockProfit.com announces an investment report featuring BioSphere Medical Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

17 May 2010

Titan Pharmaceuticals reports total revenues of $2.4M for first-quarter 2010

Titan Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010.

17 May 2010

China Biologic first-quarter revenues up 28.1% to $27.1 million

China Biologic Products, Inc., one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd. and its equity investment in Xi'an Huitian Blood Products Co., Ltd., today reported financial results for its first quarter ended March 31, 2010.

17 May 2010